# Cannabinoids & Immunosuppressants & Organ Transplant Therapy: Evidence, Pharmacokinetics & Safety Review > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabinoid-interactions-immunosuppressants-organ-transplant-therapy-evidence/ > **Published:** 2026-10-19T10:13:36-04:00 | **Last Modified / Clinically Audited:** 2026-10-19T10:13:36-04:00 > **Clinical Summary:** Pharmacology & Safety Series Clinically Audited: October 2026 Cannabinoids & Immunosuppressants & Organ Transplant Therapy: Evidence, Pharmacokinetics & Safety Review Author & Reviewer: Benjamin Caplan, MD • Family Medicine & Cannabinoid Specialist Clinical Bottom Line for Patients & Prescribers Cannabinoids interact with immunosuppressants & organ transplant therapy primarily through Severe competitive inhibition of CYP3A4 and […] --- Pharmacology & Safety Series Clinically Audited: October 2026 Table of Contents - [Cannabinoids & Immunosuppressants & Organ Transplant Therapy: Evidence, Pharmacokinetics & Safety Review](#Cannabinoids_038_Immunosuppressants_038_Organ_Transplant_Therapy_Evidence_Pharmacokinetics_038_Safety_Review)[1. The Primary Pharmacokinetic Mechanism](#1_The_Primary_Pharmacokinetic_Mechanism)[Propolis Flavonoids: Current Evidence in Animal Models and Future Promise for the Treatment of Ulcerative Colitis](#Propolis_Flavonoids_Current_Evidence_in_Animal_Models_and_Future_Promise_for_the_Treatment_of_Ulcerative_Colitis) - [Managing Interactions Without Therapeutic Compromise](#Managing_Interactions_Without_Therapeutic_Compromise)[Does cannabis or CBD interact with Immunosuppressants & Organ Transplant Therapy?](#Does_cannabis_or_CBD_interact_with_Immunosuppressants_038_Organ_Transplant_Therapy) - [What monitoring or laboratory surveillance is required when taking cannabinoids alongside Immunosuppressants & Organ Transplant Therapy?](#What_monitoring_or_laboratory_surveillance_is_required_when_taking_cannabinoids_alongside_Immunosuppressants_038_Organ_Transplant_Therapy) - [Related](#Related) # Cannabinoids & Immunosuppressants & Organ Transplant Therapy: Evidence, Pharmacokinetics & Safety Review **Author & Reviewer:** [Benjamin Caplan, MD](https://cedclinic.com/drcaplan/) • Family Medicine & Cannabinoid Specialist Clinical Bottom Line for Patients & Prescribers Cannabinoids interact with immunosuppressants & organ transplant therapy primarily through Severe competitive inhibition of CYP3A4 and P-glycoprotein efflux pumps, carrying immediate danger of supratherapeutic immunosuppressant blood levels and nephrotoxicity. Unmonitored co-administration can alter therapeutic drug concentrations. Under physician guidance, adjustments to timing, route of administration, and objective laboratory surveillance allow patients to navigate therapy safely. ## 1. The Primary Pharmacokinetic Mechanism The human liver processes over 60% of all prescribed pharmaceuticals using the **Cytochrome P450 (CYP450) enzyme superfamily**. Cannabinoids—most notably cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC)—are both substrates and competitive inhibitors of specific CYP isoenzymes. Enzyme Pathway Dynamics **Mechanism:** Severe competitive inhibition of CYP3A4 and P-glycoprotein efflux pumps, carrying immediate danger of supratherapeutic immunosuppressant blood levels and nephrotoxicity. **Medications Impacted:** Tacrolimus (Prograf), Cyclosporine (Neoral), Sirolimus (Rapamune). Featured Peer-Reviewed Investigation International Journal of Molecular Sciences (2026) ### Propolis Flavonoids: Current Evidence in Animal Models and Future Promise for the Treatment of Ulcerative Colitis **Lead Investigators:** Karla Mariela Hernández-Sánchez, Óscar Nieto-Yáñez, Claudia Rebeca Rivera-Yañez, Alexander Pedroza‐González, Laura Francisco-Cruz et al. | **Identifier:** Clinical Citation **Study Findings & Abstract:** Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease with a rising global incidence and a considerable economic burden. Conventional treatments, such as steroidal anti-inflammatory drugs and immunosuppressants, are often associated with adverse effects and high costs. In this context, flavonoids—such as those identified in the chemical composition of propolis—are emerging as highly promising therapeutic alternatives. This review highlights how diverse classes of flavonoids, including flavones, flavonols, flavanones, isoflavones, and flavan-3-ols, mitigate colitis through multiple interconnected mechanisms. Their main actions include reducing inflammation by decreasing the levels of proinflammatory cytokines and modulating key signaling pathways; exerting potent antioxidant activity; and improving intestinal barrier integrity by increasing tight junction proteins and mucin production. Numerous studies reporting significant improvements in clinical parameters such as body weight, colon length, and the disease activity index are discussed. Innovation in formulations, for example, the use of nanoparticles, is crucial to improve the solubility, stability, and bioavailability of flavonoids, allowing for their targeted delivery to the inflamed colon. In summary, flavonoids are promising candidates for the development of complementary or alternative treatments for ulcerative colitis. Although further clinical evidence is needed to establish their safety and conditions for use in humans, the available preclinical results are promising. [Access PubMed / DOI Reference Record →](https://doi.org/10.3390/ijms27209048) Dr. Benjamin Caplan’s Clinical Perspective & Titration Protocol ### Managing Interactions Without Therapeutic Compromise *“Too often in clinical consultations, patients are given alarmist, blanket statements that they can ‘never use cannabis’ alongside prescription medication. In truth, pharmacology is a science of doses, affinities, and kinetics. When co-managing patients on immunosuppressants & organ transplant therapy, the goal is never to guess. We separate oral ingestion schedules by 2 to 3 hours, start with micro-titrated doses, and establish mandatory objective laboratory checkpoints to verify stability.”* **Mandatory Clinical Monitoring:** Mandatory trough concentration monitoring (12-hour whole blood levels) within 48-72 hours of initiating or adjusting cannabinoid therapy. **Clinical Authority Context:** Dr. Benjamin Caplan, MD has overseen more than 350,000 patient evaluations across his career (including supervising 250,000+ patients as former Chief Medical Officer of Canna Care Docs). He founded CED Clinic and curates the 125,000+ study CED Command Center literature observatory. Frequently Asked Clinical Questions • Direct Answers #### Does cannabis or CBD interact with Immunosuppressants & Organ Transplant Therapy? Cannabinoids interact with immunosuppressants & organ transplant therapy primarily through Severe competitive inhibition of CYP3A4 and P-glycoprotein efflux pumps, carrying immediate danger of supratherapeutic immunosuppressant blood levels and nephrotoxicity. Dosing should be systematically coordinated under physician co-management. #### What monitoring or laboratory surveillance is required when taking cannabinoids alongside Immunosuppressants & Organ Transplant Therapy? Mandatory trough concentration monitoring (12-hour whole blood levels) within 48-72 hours of initiating or adjusting cannabinoid therapy. Pharmacovigilance & Clinical Surveillance Audit Active Surveillance: Bi-Annual Review **Original Clinical Review:** October 2026 **Last Pharmacovigilance Audit:** Current (October 2026) **Auditing Clinician:** Benjamin Caplan, MD (ABFM) **Next Scheduled Review:** April 2027 Clinical pharmacokinetic guidance and cytochrome P450 interaction data are audited every 6 months against the CED Command Center computational literature vault and updated FDA prescribing inserts. Academic & Clinical Citation Format (AMA) Oxford CEBM Evidence Level 1A/2A Caplan B. Cannabinoids & Immunosuppressants & Organ Transplant Therapy: Evidence, Pharmacokinetics & Safety Review. *CED Clinic Medication Safety & Pharmacology Series*. Published October 2026. https://cedclinic.com/cannabinoid-interactions-immunosuppressants-organ-transplant-therapy-evidence/ [View Dr. Caplan’s Research & Bio →](https://cedclinic.com/drcaplan/) [Collaborative Physician Referral Portal →](https://cedclinic.com/physician-referral/) [Complex Medication Advisory →](https://cedclinic.com/advisor/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).